Treats osteoarthritis or rheumatoid arthritis. Sold as Arthrotec. Every FDA application for this active ingredient: 1 branded and 7 generic.
As of Nov 16, 2026, FDA lists 8 applications for Diclofenac Sodium; Misoprostol (sold as Arthrotec), first approved Dec 24, 1997, with 0 new uses approved and 0 published complete response letters.
| Diclofenac Sodium-Misoprostol | Part D | $4.4M | -26% | 9,519 |
| Arthrotec 75 | Part D | $452K | -8% | 112 |
| Arthrotec 50 | Part D | $150K | +2% | 38 |
| Dec 24, 1997 | ArthrotecNDA 20607 · New combination | Pfizer | 24 | Marketed |
| Jul 9, 2012 | Diclofenac Sodium And MisoprostolANDA 201089 | Actavis Labs Fl Inc | 2 | Marketed |
| May 9, 2013 | Diclofenac Sodium And MisoprostolANDA 200158 | Sandoz | 8 | Discontinued |
| Mar 14, 2014 | Diclofenac Sodium And MisoprostolANDA 200540 | Exela Holdings | 3 | Discontinued |
| Nov 25, 2016 | Diclofenac Sodium And MisoprostolANDA 203995 | Amneal Pharms | 6 | Marketed |
| Feb 19, 2020 | Diclofenac Sodium And MisoprostolANDA 205143 | Yung Shin Pharm | 5 | Marketed |
| Jul 15, 2021 | Diclofenac Sodium And MisoprostolANDA 204355 | Micro Labs | 4 | Marketed |
| Jun 12, 2023 | Diclofenac Sodium And MisoprostolANDA 206771 | Zydus Pharms | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA